NEW YORK (GenomeWeb) — Lucence Diagnostics has partnered with Singapore Diagnostics to distribute its line of blood-based cancer diagnosis and screening tests in the Philippines, the companies announced today.
Lucence's tests are based on its patented sequencing technology and are designed to detect DNA fragments shed by a tumor into the blood.The tests target the most common cancers in Asia such as breast, colon, lung and nasopharyngeal cancer.
Additional terms of the agreement were not disclosed.
In recent months, Lucence has signed distribution agreements with Bangkok Molecular Genetics in Thailand and Quest Laboratories in Singapore.